Compare AbCellera Biologics Inc (ABCL) vs Noble Corporation plc (NE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Noble Corporation plc — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Noble Corporation plc trades at $39.3 (market cap $6.12B). The key difference: Noble Corporation plc is far larger — about 2.6× AbCellera Biologics Inc's market cap, and Noble Corporation plc pays a 5.21% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NE | |
|---|---|---|
Market Cap | $2.35B | $6.12B |
Sector | Health | Technology |
52-Week High | $8.12 | $54.37 |
52-Week Low | $2.78 | $25.70 |
Enterprise Value | $1.99B | $7.37B |
Dividend Yield | — | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Noble Corporation (NE) trades at $37.41, down 1.53% today, with technical indicators showing a bearish trend despite oversold RSI readings. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing in previous quarters. Fundamentals show steady revenue around $3.3 billion with improving net margins to 7.17% in 2026. Noble recently secured a new three-well drilling contract with BP and completed a $800 million senior notes offering to strengthen its financial position.
The stock presents a compelling valuation case with analyst consensus target of $53.33 representing 43% upside potential. However, recent earnings misses and bearish technical signals suggest near-term volatility. The offshore drilling specialist benefits from contract wins and conservative balance sheet management, though execution risks and oil price sensitivity remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
